Listed in America's Top Doctors, Castle Connolly Medical Ltd, 2003-20092003-2009, Listed in Best Doctors in America, Best Doctors, Inc
2008, Listed in Best Doctors in America for Cancer, Best Doctors, Inc
2002, Outstanding Achievement Award, Urologic Oncology Branch, National Cancer Institute
1995, CIAO Award for Medicine
Editorial Responsibilities
Editor or Editorial Boards:
Associate Editor, The 5 Minute Urology Consult, 2008-present
Community Editor, Urologic Surgery, American College of Surgeons Web Portal, 2007-present
Editorial Board, Cornell University Medical College Reports on Men’s Urologic Health, 2006-present
Associate Editor, The Journal of Men’s Health & Gender, 2003-present
Urology Times, Hands-On Editor, 2002-present
Editor-in-Chief, Yearbook of Urology, 1997-present
Editorial Board, Urology Research and Treatment, 1999-present
Editorial Board, Urologia Internationalis, 1997-present
Editorial Consultant, The Paget Society, 1999-present
The Prostate Journal, 1997-present
Editorial Board, Infections in Urology, 1991-present
Editorial Advisory Board, Surgical Rounds, 1990-present
Editorial Board, Annals of Surgical Oncology, 1997-2003
Reviewer:
Journal of Urology
Urology
Urologic Oncology
Journal of the National Cancer Institute
Cancer
Cancer Research
New England Journal of Medicine
Journal of Clinical Oncology
Prostate Cancer
European Urology
Major National Committees
Steering Committee, Prostate Cancer Chemoprevention Trial
Steering Committee, NIH PLCO Cancer Screening Trial
Chairman, Prostate Subcommittee NCI PLCO Cancer Screening Trial
Medical Advisory Committee, Prostate Intervention Versus Observation Trial
(PIVOT)
Commission on Cancer of the American College of Surgeons
Cochrane Collaboration in Prostatic Diseases
AUA/Pfizer Visiting Professor Review Board
Steering Committee, CAMUS Trial (NIH/NIDDK)
Chairman, Steering Committee, REDUCE Trial (Dutasteride Chemoprevention Trial)
NCI, Biorepository Scientific Advisory Panel
Panel Member, Blue Ribbon Prostate Institution Oral Examiner, Exam Committee, American
Selected Recent Journal Articles (of 200)
Behalf of the NCI Institute Breast & Prostate Cancer Cohort Consortium: Schumacher FR, Cheng I, Annual screening for prostate cancer did not reduce mortality from prostate cancer. ACP J Club. 2009;150:JC6-4 Abstract of Andriole GL, Crawford ED, Grubb RL III, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O’Brien B, Clapp GS, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK and Berg CD for the PLCO Project Team: Mortality Results from a Prostate-Cancer Screening Trial. NEJM 360:1310-1319, 2009.
Andriole GL: Prostate Cancer Risk: Overview of the Disease, Predictive Factors, and Potential Targets for Risk Reduction. Guest Editor, Urology 73(5A):S1-3, 2009.
Andriole GL: Overview of Pivotal Studies for Prostate Cancer Risk Reduction, Past and Present. Urology 73(5A):S36-43, 2009.
Croswell, J.M., Kramer, B.S., Kreimer, A.E., Prorok, P.C., Xu, J.L., Baker, S.G., Fagerstrom, R., Riley, T.L., Clapp, J.D., Berg, C.D., Gohagan, J.K., Andriole, G.L., Chia, D., Church, T.R., Crawford, E.D., Fouad, M.N., Gelmann, E.P., Lamerato, L., Reding, D.J., and Schoen, R.E.: Cumulative Incidence of False-Positive Results in Repeated Multimodal Cancer Screening. Annals of Family Medicine 7(3): 212-222, 2009
Partridge E, Kreimer AR, Greenlee RT, Williams C, Xu JL, Church TR, Kessel B, Johnson CC, Weissfeld JL, Isaacs C, Andriole GL, Ogden S, Ragard LR, Buys SS for the PLCO Project Team: Results from four rounds of ovarian cancer screening in a randomized trial. Obstet & Gynecol 113(4):775-782, 2009.
Andriole GL, Crawford ED, Grubb RL III, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O’Brien B, Clapp GS, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK and Berg CD for the PLCO Project Team: Mortality Results from a Prostate-Cancer Screening Trial. NEJM 360:1310-1319, 2009.
Schroder, F.H., Roobol, M.J., Andriole, G.L. and Fleshner, N: Defining Increased Future Risk of Prostate Cancer: Evidence from a Population-Based Screening Cohort. J Urol 181:69-74, 2009.
Leitzman MF, Ahn J, Albanes D. Hsing AW, Schatzkin A, Chang SC, Huang WY, Wiess JM, Danforth KN, Grubb RL, Andriole GL; for the Prostate, Lung, Colorectal and Ovarian (PLCO) Trial Project Team: Diabetes mellitus and prostate cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Causes Control 19(10):1267-1276, 2008.
Anast, J.W., Andriole, G.L. and Grubb, R.L.: Managing the Local Complications of Locally Advanced Prostate Cancer. Curr Urol Rep 8(3):211-216, 2007.
Andriole, G.L., Humphrey P.A., Serfling, R.J. and Grubb, R.L.: High-Grade Prostate Cancer in the Prostate Cancer Prevention Trial: Fact or Artifact? JNCI 99(18):1355-1356, 2007
Andriole, G.L.: Words of Wisdom. RE: Extended 21-Sample Needle Biopsy Protocol for diagnosis of Prostate Cancer in 1000 Consecutive Patients. Eur Urology 52:608, 2007.
Andriole GL, Marberger M, Roehrborn CG. Clinical usefulness ofserum prostate specific antigen for the detection of prostate cancer ispreserved in men receiving the dual 5alpha-reductase inhibitordutasteride. Journal of Urology. 2006;175(5):1657-1662.
Bullock TL, Andriole GL Jr. Emerging drug therapies for benignprostatic hyperplasia. Expert Opin Emerg Drugs. 2006;11(1):111-123.
Kirsh VA, Hayes RB, Mayne ST, Chatterjee N, Subar AF, Dixon LB, AlbanesD, Andriole GL, Urban DA, Peters U; PLCO Trial. Supplemental anddietary vitamin E, beta-carotene, and vitamin C intakes and prostatecancer risk. Journal of the National Cancer Institute.2006;98(4):245-254.
Cross AJ, Peters U, Kirsh VA, Andriole GL, Reding D, Hayes RB, Sinha R.A prospective study of meat and meat mutagens and prostate cancer risk.Cancer Research. 2005;65(24):11779-11784.
Bhayani, S.B. and Andriole, G.L.: Pure Laparoscopic RadicalHeminephrectomy and Partial Isthmusectomy for Renal Cell Carcinoma in aHorseshoe Kidney: Case Report and Technical Considerations. Urology66(4):880, 2005.
Andriole, G.L., Bostwick, D., Civantos, F, Epstein, J., Lucia, M.S.,McDonnell, J., and Roehrborn, C.G.: The Effects of 5α-ReductaseInhibitors on the Natural History, Detection and Grading of ProstateCancer: Current State of Knowledge. J Urology 174:2098-104, 2005.
Andriole, G.L.: Prostate Specific Antigen Based Prostate CancerScreening: Accumulating Evidence of Efficacy but PersistentUncertainty. Editorial Comment J Urology 174(2):413-414, 2005.
Reisiger, K., Tran, V., Figenshau, R.S., Andriole, G.L., Landman, J.:Single-setting bilateral laparoscopic renal surgery: assessment ofsingle-stage procedure. Urology 65(5):892-897, 2005.
Andriole, G.L., Levin, D.L., Crawford, E.D., Gelmann, E.P., Pinsky,P.F., Chia, D., Kramer, B.S., Reding, D., Church, T.R., Grubb, R.L.,Izmirlian, G., Ragard, L.R., Clapp, J.D., Prorok, P.C., and Gohagan, J.K. for the PLCO Project Team: Prostate Cancer Screening in theProstate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial:Findings from the Initial Screening Round of a Randomized Trial. JNCI97(6):433-438, 2005.
Iczkowski, K.A., Qiu, J., Qian, J., Somerville, M.C., Rittmaster, R.S.,Andriole, G.L., and Bostwick, D.G.: The Dual 5-Alpha-ReductaseInhibitor Dutasteride Induces Atrophic Changes and Decreases RelativeCancer Volume in the Human Prostate. J. Urology 65(1):76-82, 2005.
Pinsky, P.F., Andriole, G.L., Kramer, B., Hayes, R., Prorok, P. andGohagan, J for the Prostate. Lung, Colorectal and Ovarian Project Team:Prostate Biopsy Following a Positive Screen in the Prostate, Lung,Colorectal and Ovarian (PLCO) Cancer Screening Trial. J Urology173(3):746-751, 2005.
Andriole, G.L., Reding, D., Hayes, R.B., Prorok, P.C., Gohagan, J.K.,on behalf of the PLCO Steering Committee. The Prostate, Lung, Colon,and Ovarian (PLCO) Cancer Screening Trial: Status and Promise. Urol Onc22:358-361, 2004.
Andriole, G.L., Bruchovsky, N., Chung, L., Matsumoto, A., Rittmaster,R., Roehrborn, C., Russell, D., and Tindall, D.: Dihydrotestosterone(DHT) and the Prostate: The Scientific Rationale for 5-ReductaseInhibitors in the Treatment of Benign Prostatic Hyperplasia. J Urology172(4):1399-1403, 2004.
Andriole, G.L., Bostwick, D., Brawley, O., Gomella, L., Marberger, M.,Tindall, Breed, S., Somerville, M. and Rittmaster, R., for the REDUCEStudy Group. Chemoprevention of Prostate Cancer in High Risk Men:Rationale and Design of the REDUCE Trial. J Urology 172(4):1314-1317,2004.
Andriole, G.L., Humphrey, P., Ray, P., Gleave, M.E., Trachtenberg, J.,Thomas, L.N., Lazier, C.B. and Rittmaster, R.S.: Effect of the Dual5-Reductase Inhibitor Dutasteride on Markers of Tumor Regression inProstate Cancer. J Urology 172(3):915-919, 2004.
Anast J.W., Andriole, G.L., Bismar, T.A., Yan, Y., and Humphrey, P.A.:Relating Biopsy and Clinical Variables to Radical ProstatectomyFindings: Can Insignificant and Advanced Prostate Cancer be Predictedin a Screening Population? Urology 64(3):544-550, 2004.
Andriole, G.L., Roehrborn, C., Schulman, C., Slawin, K.M., Somerville,M. and Rittmaster, R.S.: Effect of Dutasteride on the Detection ofProstate Cancer in Men with Benign Prostatic Hyperplasia. Urology64:537-543, 2004.
Landman J, Venkatesh R, Vanlangendonck R, Andriole GL. Application of afixed retractor system to facilitate laparoscopic radicalprostatectomy. Journal of Urology 2004; 171(2 Pt 1):783-785
Kang, D., Andriole, G.L., van de Vooren R.C., Crawford, E.D., Chia, D.,Urban, D.A., Reding, D., Huang, W.Y., and Hayes, R.B.: Risk Behaviorsand Benign Prostatic Hyperplasia. BJU International 93:1241-1245, 2004.
McConnell JD, Roehrborn CG, Bautista OM, Andriole GL, Dixon CM, KusekJW, et al. for the Medical Therapy of Prostatic Symptoms (MTOPS)Research Group. The long-term effects of doxazosin, finasteride and thecombination on the clinical progression of benign prostatichyperplasia. New England Journal of Medicine 2003; 349(25):2385-2396
O’Leary M, Roehrborn C, Andriole GL, Nickel JC, Boyle P, Hoefner K.Improvements in benign prostatic hyperplasia-specific quality of lifewith dutasteride, the novel dual 5alpha-reductase inhibitor. BritishJournal of Urology 2003; 92(3):262-266
Bhayani SB, Clayman RV, Sundaram CP, Landman J, Andriole G, FigenshauRS, Bullock A, Brandes S, Shalhav A, McDougall E, Kibel AS. Surgicaltreatment of renal neoplasia: evolving toward a laparoscopic standardof care. Urology 2003; 62(5):821-826
Landman J, Venkatesh R, Lee D, Vanlangendonck R, Morrissey K, AndrioleGL, Clayman RV, Sundaram CP. Renal hypothermia achieved by retrogradeendoscopic cold saline perfusion: Technique and initial clinicalapplication. Urology 2003; 61(5):1023-1025
Lowe FC, McConnell JD, Hudson PB, Romas NA, Boake R, Lieber M, ElhilaliM, Geller J, Imperto-McGinely J, Andriole GL, et al: Long-term 6 yearexperience with finasteride in patients with benign prostatichyperplasia. Urology 2003; 61(4):791-796
Emberton M, Andriole GL, de la Rosette J, Djavan B, Hoefner K, VelaNavarrete R, Nordling J, Roehrborn C, Schulman C, Teillac P, Tubaro A,Nickel JC. BPH: A progressive disease of the aging male. Urology 2003;61(2):267-273
Oh J, Andriole GL. Carcinoma of the penis: epidemiology: incidence, risk factors, and clinical presentation. UpToDate May, 2003
Andriole GL, Kirby R. Safety and tolerability of the dual5alpha-reductase inhibitor dutasteride in the treatment of benignprostatic hyperplasia. European Urology 2003; 44(1):82-88.